Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q4 FY21 results · Jan–Mar 2021
Alkem Laboratories reported revenue from operations of ₹2,192.16 crore (up 7.0% from Q4 FY20) and net profit of ₹249.22 crore (up 30.1% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,192.16 | 2,048.99 | +7.0% | 2,318.05 | −5.4% |
| Other income | 46.28 | 27.47 | +68.5% | 96.40 | −52.0% |
| Total income | 2,238.44 | 2,076.46 | +7.8% | 2,414.45 | −7.3% |
| Profit before tax | 258.16 | 235.30 | +9.7% | 543.44 | −52.5% |
| Net profit for the period | 249.22 | 191.54 | +30.1% | 463.85 | −46.3% |
| Attributable to shareholders of the company | 239.99 | 188.77 | +27.1% | 450.96 | −46.8% |
| EPS, basic (₹) | 20.07 | 15.79 | +27.1% | 37.72 | −46.8% |
| Net margin (%) | 11.4 | 9.3 | 20.0 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,917.47 | 1,687.52 | +13.6% | 1,778.75 | +7.8% |
| Other income | 48.77 | 25.92 | +88.2% | 72.46 | −32.7% |
| Total income | 1,966.24 | 1,713.44 | +14.8% | 1,851.21 | +6.2% |
| Profit before tax | 395.66 | 306.43 | +29.1% | 456.78 | −13.4% |
| Net profit for the period | 362.74 | 271.21 | +33.7% | 400.98 | −9.5% |
| EPS, basic (₹) | 30.34 | 22.68 | +33.7% | 33.54 | −9.5% |
| Net margin (%) | 18.9 | 16.1 | 22.5 |
Consolidated
- Filed with BSE
- 26 May 2021, 08:21 IST
- Board meeting
- 25 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 May 2021, 08:21 IST
- Board meeting
- 25 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE